Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.

Teruo Inamoto,Ryo Sato,Yuto Matsushita,Taizo Uchimoto, K O Nakamura,Kazumasa Komura,Kazuki Nishimura,Yusuke Yano,Kyosuke Nishio, Shoko Kinoshita, Tatsuo Fukushima,Tomohisa Matsunaga,Keita Nakamori,Takeshi Tsutsumi,Takuya Tsujino,Hirofumi Uehara,Kiyoshi Takahara,Hideaki Miyake,Haruhito Azuma

Cancer diagnosis & prognosis（2023）

引用 0|浏览19

暂无评分

摘要

Given that response when evaluated at a later point during pembrolizumab treatment more favorably reflected improved survival than when assessed earlier, physicians may be encouraged to wait until at least the termination of pembrolizumab treatment to determine the best response.

查看译文

关键词

metastatic urothelial carcinoma,pembrolizumab treatment,urothelial carcinoma,japanese patients

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要